Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343715 | 1.00 | RHEB (0.50) | RHEBSIRT2SIRT1PKN1PKN2 | |
| SCHEMBL30343735 | 0.89 | RHEB (0.51) | RHEBSIRT2SIRT1PKN1PKN2 | |
| SCHEMBL19994743 | 0.89 | RHEB (0.51) | RHEBSIRT2SIRT1PKN1PKN2 | |
| SCHEMBL1664192 | 0.87 | ALDH1A1 (0.53) | SIRT2SIRT1LRRK2CHEK2 | |
| SCHEMBL1663221 | 0.81 | PARP1 (0.52) | SIRT2SIRT1PARP1CBFBCHEK2 | |
| SCHEMBL8772505 | 0.81 | SIRT2 (0.59) | SIRT2SIRT1CBFBCHEK2ACHE | |
| SCHEMBL1666722 | 0.81 | KDM4E (0.50) | SIRT2SIRT1PARP1CBFBCHEK2 | |
| SCHEMBL8768585 | 0.80 | CHEK2 (0.56) | SIRT2SIRT1LRRK2CHEK2 | |
| SCHEMBL8769224 | 0.80 | CHEK2 (0.56) | SIRT2SIRT1LRRK2CHEK2 | |
| SCHEMBL19994744 | 0.80 | PKN1 (0.61) | RHEBSIRT2SIRT1PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | RHEB 500/4885SIRT2 1935/4885SIRT1 2148/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | RHEB 798/4885SIRT2 1954/4885SIRT1 2241/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | RHEB 798/4885SIRT2 1954/4885SIRT1 2241/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | RHEB 839/4885SIRT2 1990/4885SIRT1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.